Summary: FierceBiotech chronicles MAPS’ ongoing road to potential FDA approval of MDMA-assisted therapy for the treatment of PTSD, highlighting the uncertainty facing the broader medical field as rigorous studies continue to demonstrate the efficacy of psychedelic-assisted therapies. Amy Emerson, Chief Executive Officer of MAPS Public Benefit Corporation (MAPS PBC), explains the unique regulatory factors that apply to the integration of psychedelics into mainstream medicine.
Originally appearing here.
